Status:

RECRUITING

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

Lead Sponsor:

Ain Shams University

Conditions:

Dexmedetomidine

Adjuvant

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

Detailed Description

Scalp block is proposed as a multimodal approach to preventing postoperative pain and hemodynamic responses to previous noxious stimulation during the operation. The use of adjuvants, such as dexmede...

Eligibility Criteria

Inclusion

  • Age from 18 to 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Undergoing supratentorial elective planned craniotomies.

Exclusion

  • Patients refusal.
  • History of known allergy to the used local anesthetic or dexmedetomidine.
  • Bleeding disorders.
  • Evidence of local infection at the site of injection.
  • Emergency craniotomy.
  • Psychotic disorder.
  • Patients who will not be extubated in the operating room after surgery.

Key Trial Info

Start Date :

May 29 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06993922

Start Date

May 29 2025

End Date

November 1 2025

Last Update

May 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ain Shams University

Cairo, Egypt, 11591

Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy | DecenTrialz